Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.

Cytometry. Part B, Clinical cytometry - 1 Jan 2014

Zeijlemaker W, Gratama J W, Schuurhuis G J

Abstract excerpt

Detection of minimal residual disease is recognized as an important post-therapy risk factor in acute myeloid leukemia patients. Two most commonly used methods for residual disease monitoring are real-time quantitative polymerase chain reaction and multiparameter flow cytometry. The results so far are very promising, whereby it is likely that minimal residual disease results will enable to guide future...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clonal Evolution
Share to Drug Resistance, Neoplasm
Share to Flow Cytometry

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 24151248
DOI: 10.1002/cyto.b.21134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.PMID 24151248Read ↗

Tumor heterogeneity makes AML a “moving target” for detection of residual diseaseSemantic proximity Read ↗

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Semantic proximity Read ↗

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation SequencingSemantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Assessment of Minimal Residual Disease in Standard-Risk AML.Semantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Detection of minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.